Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],160-300,18219,DB01097,Leflunomide
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],0 and 4.3,18220,DB01097,Leflunomide
,23179005,clearances,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],1.1 and 3.4,18221,DB01097,Leflunomide
,23179005,Total amount of teriflunomide removed,Total amount of teriflunomide removed was 5.8-8.8 μg per dialysis session.,Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),μg,5.8-8.8,18222,DB01097,Leflunomide
,8591650,bio-availability,This drug's bio-availability averages 25-35% but is highly variable.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),%,25-35,29074,DB01097,Leflunomide
,8591650,elimination half-life,CSA is metabolized to numerous metabolites by the liver and its elimination half-life is 6-12 hours in the absence of severe liver disease.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),h,6-12,29075,DB01097,Leflunomide
,8591650,elimination half-life,"Its active metabolite is excreted renally to a large degree, with a prolonged elimination half-life of about 11 days.","Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),d,11,29076,DB01097,Leflunomide
,7725383,recoveries,"In human blood, the method exhibited good analytic recoveries from 78 +/- 13.5% to 108 +/- 4.8% (mean +/- SD) for drug concentrations ranging from 400 to 100,000 micrograms/L.",Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725383/),%,78,37535,DB01097,Leflunomide
,7725383,recoveries,"In human blood, the method exhibited good analytic recoveries from 78 +/- 13.5% to 108 +/- 4.8% (mean +/- SD) for drug concentrations ranging from 400 to 100,000 micrograms/L.",Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725383/),%,108,37536,DB01097,Leflunomide
,7725383,sensitivity,"When using a sample volume of 0.25 ml the sensitivity of the method was found to be 400 micrograms/L, with a working standard range of up to 200,000 micrograms/L.",Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725383/),,400,37537,DB01097,Leflunomide
,7725383,sensitivity,The sensitivity of the method can be increased to 40 micrograms/L when 1.0 ml of sample is used.,Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725383/),[μg] / [l],40,37538,DB01097,Leflunomide
,12060531,"T1/2,ka","Leflunomide was absorbed rapidly with T1/2,ka of between 1.15 h and 2.23 h in single oral administration.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,1.15,41797,DB01097,Leflunomide
,12060531,"T1/2,ka","Leflunomide was absorbed rapidly with T1/2,ka of between 1.15 h and 2.23 h in single oral administration.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,2.23,41798,DB01097,Leflunomide
,12060531,ke,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,211,41799,DB01097,Leflunomide
,12060531,ke,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,170,41800,DB01097,Leflunomide
,12060531,ke,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,252,41801,DB01097,Leflunomide
,12060531,Tmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,13,41802,DB01097,Leflunomide
,12060531,Tmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,13,41803,DB01097,Leflunomide
,12060531,Tmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,9,41804,DB01097,Leflunomide
,12060531,Cmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],2.0,41805,DB01097,Leflunomide
,12060531,Cmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],5.2,41806,DB01097,Leflunomide
,12060531,Cmax,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],6.7,41807,DB01097,Leflunomide
,12060531,AUC,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[h·mg] / [l],647,41808,DB01097,Leflunomide
,12060531,AUC,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[h·mg] / [l],1344,41809,DB01097,Leflunomide
,12060531,AUC,"The major pharmacokinetic parameters of A771726 in 20, 40, and 60 mg groups were T1/2,ke(h): 211 +/- 18, 170 +/- 24, 252 +/- 26; Tmax(h): 13 +/- 12, 13 +/- 4, 9 +/- 5; Cmax (mg/L): 2.0 +/- 0.5, 5.2 +/- 0.6, 6.7 +/- 1.5; AUC (mg . h . L-1): 647 +/- 137, 1344 +/- 191, 2555 +/- 907, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[h·mg] / [l],2555,41810,DB01097,Leflunomide
,12060531,trough concentration,The mean trough concentration was between 32.0 mg/L and 39.7 mg/L.,Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],32.0,41811,DB01097,Leflunomide
,12060531,trough concentration,The mean trough concentration was between 32.0 mg/L and 39.7 mg/L.,Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],39.7,41812,DB01097,Leflunomide
,12060531,Cmax,"The Cmax, Tmax, AU C0- 24 were (41.5 +/- 2.4) mg/L, (307 +/- 75) h, and (22099 +/- 1234) mg . h . L-1, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),[mg] / [l],41.5,41813,DB01097,Leflunomide
,12060531,Tmax,"The Cmax, Tmax, AU C0- 24 were (41.5 +/- 2.4) mg/L, (307 +/- 75) h, and (22099 +/- 1234) mg . h . L-1, respectively.",Pharmacokinetics of leflunomide in Chinese healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060531/),h,307,41814,DB01097,Leflunomide
,21615755,elimination,"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[μg] / [ml],15.2,90919,DB01097,Leflunomide
,21615755,distribution,"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),h,1.5,90920,DB01097,Leflunomide
,21615755,elimination half-lives,"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),h,71.8,90921,DB01097,Leflunomide
,21615755,area under the curve (AUC(0 → ∞),"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[h·μg] / [ml],3723,90922,DB01097,Leflunomide
,21615755,mean residence time (MRT,"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),h,93,90923,DB01097,Leflunomide
,21615755,clearance (Cl(obs),"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[ml] / [h·kg],1.1,90924,DB01097,Leflunomide
,21615755,volume of distribution at steady state (Vd(ss),"Mean pharmacokinetic parameter values after a single i.v. dose of A77 1726 were distribution (A) and elimination (B) intercepts (15.2 μg/mL and 34.5 μg/mL, respectively), distribution and elimination half-lives (1.5 and 71.8 h, respectively), area under the curve (AUC(0 → ∞); 3723 μg*h/mL), mean residence time (MRT; 93 h), clearance (Cl(obs); 1.1 mL/kg/h), and volume of distribution at steady state (Vd(ss); 97 mL/kg).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[ml] / [kg],97,90925,DB01097,Leflunomide
,21615755,absorption,"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[1] / [h],0.3,90926,DB01097,Leflunomide
,21615755,elimination rate constants,"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[1] / [h],0.01,90927,DB01097,Leflunomide
,21615755,absorption,"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),h,2.3,90928,DB01097,Leflunomide
,21615755,elimination half-lives,"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),h,59.1,90929,DB01097,Leflunomide
,21615755,AUC(0 → ∞),"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[h·μg] / [ml],3966,90930,DB01097,Leflunomide
,21615755,maximum observed plasma concentration (C(max),"Mean pharmacokinetic parameter values after a single oral dose of leflunomide were absorption and elimination rate constants (0.3 1/h and 0.01 1/h, respectively), absorption and elimination half-lives (2.3 and 59.1 h, respectively), AUC(0 → ∞) (3966 μg*h/mL), and maximum observed plasma concentration (C(max); 38 μg/mL).",Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[μg] / [ml],38,90931,DB01097,Leflunomide
,21615755,bioavailability,The bioavailability after a single oral dose of leflunomide was 100%.,Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),%,100,90932,DB01097,Leflunomide
,21615755,concentration that inhibited 50% lymphocytes (EC(50) ),The mean ± SD A77 1726 concentration that inhibited 50% lymphocytes (EC(50) ) was 16 ± 13.5 μg/mL.,Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[μg] / [ml],16,90933,DB01097,Leflunomide
,21615755,maximum A77 1726 concentration (EC(max)),The mean ± SD maximum A77 1726 concentration (EC(max)) was 61.0 ± 23.9 μg/mL.,Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615755/),[μg] / [ml],61.0,90934,DB01097,Leflunomide
,19581389,steady-state plasma concentrations,A large interindividual variability in trough A77 1726 steady-state plasma concentrations was observed (from 1.9 to 156.9 mg/l).,Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19581389/),[mg] / [l],1.9 to 156.9,131051,DB01097,Leflunomide
,19581389,steady-state plasma A77 1726 concentrations,Patients with a greater decrease in C-reactive protein (CRP) had higher average steady-state plasma A77 1726 concentrations: 49.7 +/- 39.0 mg/l in patients with DeltaCRP of more than 8.5 mg/l compared with 24.8 +/- 13.7 mg/l in patients with DeltaCRP of <or=8.5 mg/l (p = 0.015).,Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19581389/),[mg] / [l],49.7,131052,DB01097,Leflunomide
,19581389,steady-state plasma A77 1726 concentrations,Patients with a greater decrease in C-reactive protein (CRP) had higher average steady-state plasma A77 1726 concentrations: 49.7 +/- 39.0 mg/l in patients with DeltaCRP of more than 8.5 mg/l compared with 24.8 +/- 13.7 mg/l in patients with DeltaCRP of <or=8.5 mg/l (p = 0.015).,Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19581389/),[mg] / [l],24.8,131053,DB01097,Leflunomide
,10561166,total volume,"Dose escalation of SU101 above 443 mg/m(2)/wk was precluded by the total volume of infusate required, 2.5 to 3.0 L.",Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561166/),,2.5 to 3.0,158630,DB01097,Leflunomide
,10561166,elimination half-life,"SU101 was rapidly converted to SU0020, which exhibited a long elimination half-life averaging 19 +/- 12 days.",Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561166/),d,19,158631,DB01097,Leflunomide
,10561166,trough plasma SU0020 concentrations,"At the 443 mg/m(2)/wk dose level, trough plasma SU0020 concentrations during weeks 2 and 4 ranged from 54 to 522 micromol/L.",Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561166/),[μM] / [l],54 to 522,158632,DB01097,Leflunomide
,31366828,relative bioavailability,"The plasma concentration curve showed that compared with LEF group, the peak concentration of TEF microemulsion group was decreased, the half-life (t1/2) was prolonged, and the relative bioavailability of TEF microemulsion was 75.35%.",Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366828/),%,75.35,158954,DB01097,Leflunomide
,20353751,AUC(0-t),"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[h·μg] / [ml],487.3,160781,DB01097,Leflunomide
,20353751,AUC(0-t),"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[h·μg] / [ml],468.5,160782,DB01097,Leflunomide
,20353751,Cmax,"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[μg] / [ml],2.24,160783,DB01097,Leflunomide
,20353751,Cmax,"After administering a single dose of 20 mg of each leflunomide formulation, the mean AUC(0-t) and Cmax values of A771726 were 487.3 +/- 167.6 microg*h/ml and 2.24 +/- 0.85 microg/ml for the reference formulation and 468.5 +/- 148.6 microg*h/ml and 1.98 +/- 0.45 microg/ml for the test formulation, respectively.","Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20353751/),[μg] / [ml],1.98,160784,DB01097,Leflunomide
,23447478,Total concentrations,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),[mg] / [l],5.2 and 23.2,161228,DB01097,Leflunomide
,23447478,unbound concentrations,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),[mg] / [l],0.0306 and 0.1468,161229,DB01097,Leflunomide
,23447478,unbound fraction,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),%,0.367,161230,DB01097,Leflunomide
,23447478,unbound fraction,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),%,0.71,161231,DB01097,Leflunomide
,23447478,Health Assessment Questionnaire-Disability Index,Health Assessment Questionnaire-Disability Index improved from 0.5 to 0.125 at 7 months.,Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),,0.5,161232,DB01097,Leflunomide
,23447478,Health Assessment Questionnaire-Disability Index,Health Assessment Questionnaire-Disability Index improved from 0.5 to 0.125 at 7 months.,Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),,0.125,161233,DB01097,Leflunomide
,8917650,ED50,"The most promising compound (3) has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, respectively) and has shown a shorter half-life in man when compared with leflunomide.","Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917650/),[mg] / [kg],2,186358,DB01097,Leflunomide
,8917650,ED50,"The most promising compound (3) has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, respectively) and has shown a shorter half-life in man when compared with leflunomide.","Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917650/),[mg] / [kg],31,186359,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),[mg] / [l],20.9,189410,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),[mg] / [l],71.8,189411,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),[mg] / [l],129.3,189412,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),μM,77.5,189413,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),μM,266.1,189414,DB01097,Leflunomide
,10428276,Peak A77 1726 concentrations,"Peak A77 1726 concentrations were 20.9, 71.8 and 129.3 mg/l (77.5, 266.1 and 478.8 microM) for the 5, 15, and 35 mg/kg doses of leflunomide, respectively.",In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428276/),μM,478.8,189415,DB01097,Leflunomide
,30362147,m/z,"Electrospray ionization under multiple reaction monitoring was used to monitor the ion transitions for TER (m/z 269.0 → 159.9), 4-TMOA (m/z 231.9 → 160.0), internal standard teriflunomide-d4 (m/z 273.0 → 164.0) and 2-amino-4-trifluoromethyl benzoic acid (m/z 203.8 → 120.1), operating in the negative ion mode.",Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30362147/),,203.8,199923,DB01097,Leflunomide
,30362147,m/z,"Electrospray ionization under multiple reaction monitoring was used to monitor the ion transitions for TER (m/z 269.0 → 159.9), 4-TMOA (m/z 231.9 → 160.0), internal standard teriflunomide-d4 (m/z 273.0 → 164.0) and 2-amino-4-trifluoromethyl benzoic acid (m/z 203.8 → 120.1), operating in the negative ion mode.",Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30362147/),,120.1,199924,DB01097,Leflunomide
,16120064,volume of distribution,A population estimate was sought for apparent clearance (CL/F) and volume of distribution was fixed (0.155 l kg(-1)).,Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120064/),[l] / [kg],0.155,201973,DB01097,Leflunomide
,16120064,CL/F,"Final parameter estimate (% CV interindividual variability) for CL/F was 0.0184 l h(-1) (50%) (95% CI 0.0146, 0.0222).",Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120064/),[l] / [h],0.0184,201974,DB01097,Leflunomide
,12110798,survival,FK778 at 4 mg/kg prolonged median survival of the control animals from 10 days to 30.5 days.,"A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),d,10,218966,DB01097,Leflunomide
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],40,218967,DB01097,Leflunomide
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],100,218968,DB01097,Leflunomide
,31016613,maximal concentrations,"After a single administration of teriflunomide sodium and leflunomide, teriflunomide maximal concentrations were 1.32 ± 0.341 mg/L and 0.718 ± 0.169 mg/L, and area under the concentration-time curve from time zero to infinity (AUC∞) was 423 ± 229 mg·h/L and 303 ± 159 mg·h/L, respectively.","Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31016613/),[mg] / [l],1.32,247586,DB01097,Leflunomide
,31016613,maximal concentrations,"After a single administration of teriflunomide sodium and leflunomide, teriflunomide maximal concentrations were 1.32 ± 0.341 mg/L and 0.718 ± 0.169 mg/L, and area under the concentration-time curve from time zero to infinity (AUC∞) was 423 ± 229 mg·h/L and 303 ± 159 mg·h/L, respectively.","Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31016613/),[mg] / [l],0.718,247587,DB01097,Leflunomide
,31016613,area under the concentration-time curve from time zero to infinity (AUC∞),"After a single administration of teriflunomide sodium and leflunomide, teriflunomide maximal concentrations were 1.32 ± 0.341 mg/L and 0.718 ± 0.169 mg/L, and area under the concentration-time curve from time zero to infinity (AUC∞) was 423 ± 229 mg·h/L and 303 ± 159 mg·h/L, respectively.","Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31016613/),[h·mg] / [l],423,247588,DB01097,Leflunomide
,31016613,area under the concentration-time curve from time zero to infinity (AUC∞),"After a single administration of teriflunomide sodium and leflunomide, teriflunomide maximal concentrations were 1.32 ± 0.341 mg/L and 0.718 ± 0.169 mg/L, and area under the concentration-time curve from time zero to infinity (AUC∞) was 423 ± 229 mg·h/L and 303 ± 159 mg·h/L, respectively.","Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31016613/),[h·mg] / [l],303,247589,DB01097,Leflunomide
,31016613,relative bioavailability,The relative bioavailability of teriflunomide between teriflunomide sodium and leflunomide after a single dose administration was approximately 150%.,"Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31016613/),%,150,247590,DB01097,Leflunomide
,17341007,oral bioavailability,"The intraperitoneal bioavailability was estimated to be -100%, while the oral bioavailability was -30%.","Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341007/),%,-,249225,DB01097,Leflunomide
,17341007,oral bioavailability,"The intraperitoneal bioavailability was estimated to be -100%, while the oral bioavailability was -30%.","Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341007/),%,30,249226,DB01097,Leflunomide
,14999430,clearance,The median clearance of SU0020 was 0.19 l/day per m(2) and its terminal elimination half-life was 14 days.,Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14999430/),[d·l] / [m(2],0.19,262929,DB01097,Leflunomide
,14999430,terminal elimination half-life,The median clearance of SU0020 was 0.19 l/day per m(2) and its terminal elimination half-life was 14 days.,Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14999430/),d,14,262930,DB01097,Leflunomide
,8585107,half-lives (t1/2),"The half-lives (t1/2) of A77 1726 i.v. and HWA 486 p.o. administration were 3.88 +/- 2.3 and 3.18 +/- 1.6 h, respectively.",Blood distribution and single-dose pharmacokinetics of leflunomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),h,3.88,271841,DB01097,Leflunomide
,8585107,half-lives (t1/2),"The half-lives (t1/2) of A77 1726 i.v. and HWA 486 p.o. administration were 3.88 +/- 2.3 and 3.18 +/- 1.6 h, respectively.",Blood distribution and single-dose pharmacokinetics of leflunomide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),h,3.18,271842,DB01097,Leflunomide
,8585107,Vdss,The volume of distribution by both routes of administration indicates minimal distribution into tissues (Vdss p.o. = 0.14 +/- 0.03 L/kg and Vdssi.v. = 0.09 +/- 0.02 L/kg).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),[l] / [kg],0.14,271843,DB01097,Leflunomide
,8585107,Vdssi.v.,The volume of distribution by both routes of administration indicates minimal distribution into tissues (Vdss p.o. = 0.14 +/- 0.03 L/kg and Vdssi.v. = 0.09 +/- 0.02 L/kg).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),[l] / [kg],0.09,271844,DB01097,Leflunomide
,8585107,MRTp.o.,The mean residence time of A77 1726 was greater after oral administration of LEF (MRTp.o. = 10.54 +/- 2.6 h and MRTi.v. = 6.76 +/- 1.0 h).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),h,10.54,271845,DB01097,Leflunomide
,8585107,MRTi.v.,The mean residence time of A77 1726 was greater after oral administration of LEF (MRTp.o. = 10.54 +/- 2.6 h and MRTi.v. = 6.76 +/- 1.0 h).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),h,6.76,271846,DB01097,Leflunomide
,8585107,bioavailability,Identical areas under the curve suggest bioavailability was 100% (AUCp.o. = 421.16 +/- 204.5 mg.h/L and AUCi.v. = 399.75 +/- 126.9 mg.h/L).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),%,100,271847,DB01097,Leflunomide
,8585107,AUCp.o.,Identical areas under the curve suggest bioavailability was 100% (AUCp.o. = 421.16 +/- 204.5 mg.h/L and AUCi.v. = 399.75 +/- 126.9 mg.h/L).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),[h·mg] / [l],421.16,271848,DB01097,Leflunomide
,8585107,AUCi.v.,Identical areas under the curve suggest bioavailability was 100% (AUCp.o. = 421.16 +/- 204.5 mg.h/L and AUCi.v. = 399.75 +/- 126.9 mg.h/L).,Blood distribution and single-dose pharmacokinetics of leflunomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585107/),[h·mg] / [l],399.75,271849,DB01097,Leflunomide
